Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Stopped early · Phase 2

Conditions studied: Aging, Frail Older Adults

In brief

A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.

Key facts

Study ID

NCT00527046

Run by

Pfizer

People needed

396

Starts

1999-12-01

Expected to finish

2001-10-01

Last updated by the study team

2012-02-02

Who can join

Age: 65 and older, up to 84. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 65-84 years old, BMI < 30, at risk for functional decline based on SF-36, Instrumental Activities of Daily Living (per Nagy's), or 2 or more falls in prior 2 years

You may not qualify if…

• Significant history or symptoms of acute medical conditions, currently in an exercise program, pain or other conditions that would prevent participating in exercise testing

Where it is running

• Pfizer Investigational Site — Palo Alto, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — Hamden, Connecticut, United States
• Pfizer Investigational Site — New Britain, Connecticut, United States
• Pfizer Investigational Site — Lake Worth, Florida, United States
• Pfizer Investigational Site — Baltimore, Maryland, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Durham, North Carolina, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — San Antonio, Texas, United States
• Pfizer Investigational Site — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.